NCT07191717 2025-11-10Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Residual Disease, MIRI TrialJonsson Comprehensive Cancer CenterPhase 2 Not yet recruiting42 enrolled